Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 12:14:1212729.
doi: 10.3389/fendo.2023.1212729. eCollection 2023.

A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature

Affiliations
Review

A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature

Valentina Mancioppi et al. Front Endocrinol (Lausanne). .

Abstract

Lipodystrophy syndromes are characterized by a progressive metabolic impairment secondary to adipose tissue dysfunction and may have a genetic background. Congenital generalized lipodystrophy type 4 (CGL4) is an extremely rare subtype, caused by mutations in the polymerase I and transcript release factor (PTRF) gene. It encodes for a cytoplasmatic protein called caveolae-associated protein 1 (Cavin-1), which, together with caveolin 1, is responsible for the biogenesis of caveolae, being a master regulator of adipose tissue expandability. Cavin-1 is expressed in several tissues, including muscles, thus resulting, when dysfunctional, in a clinical phenotype characterized by the absence of adipose tissue and muscular dystrophy. We herein describe the clinical phenotypes of two siblings in their early childhood, with a phenotype characterized by a generalized reduction of subcutaneous fat, muscular hypertrophy, distinct facial features, myopathy, and atlantoaxial instability. One of the siblings developed paroxysmal supraventricular tachycardia leading to cardiac arrest at 3 months of age. Height and BMI were normal. Blood tests showed elevated CK, a mild increase in liver enzymes and triglycerides levels, and undetectable leptin and adiponectin concentrations. Fasting glucose and HbA1c were normal, while Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was mildly elevated. Both patients were hyperphagic and had cravings for foods rich in fats and sugars. Genetic testing revealed a novel pathogenic mutation of the CAVIN1/PTRF gene (NM_012232 exon1:c T21A:p.Y7X) at the homozygous state. The diagnosis of lipodystrophy can be challenging, often requiring a multidisciplinary approach, given the pleiotropic effect, involving several tissues. The coexistence of generalized lack of fat, myopathy with elevated CK levels, arrhythmias, gastrointestinal dysmotility, and skeletal abnormalities should prompt the suspicion for the diagnosis of CGL4, although phenotypic variability may occur.

Keywords: CGL4; PTRF; adipose tissue; leptin; lipodystrophy; muscular dystrophy.

PubMed Disclaimer

Conflict of interest statement

FP worked as a consultant for the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt Pharmaceuticals, Novo Nordisk. BA attended advisory board meetings organized by Amryt Pharmaceuticals and Regeneron Pharmaceuticals and has served as a consultant and/or received honoraria as a speaker from Third Rock Ventures, Amryt, Regeneron, AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. GC has received fees for consulting and/or received travel funds or participated in studies from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt Pharmaceuticals, Novo-Nordisk, and Rhythm Pharmaceuticals. SM received travel funds from the following company, which was involved with lipodystrophy: Amryt Pharmaceuticals. FS has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt, Novo Nordisk, Lilly, Bruno Pharma, and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Anterior and side view of the male (A) and the female (B). Pictures show the generalized loss of subcutaneous adipose tissue leading to prominence of muscular hypertrophy (more evident in the lower limbs) and prominent veins. The male patient has also progeroid facial features and an obliged posture on his toes, while the female has an acromegaloid appearance.
Figure 2
Figure 2
MRI imaging. T1-weighted MR imaging of patients 1 and 2 in comparison with a normal subject at different levels. Adipose tissue has a high signal intensity (brightness) on MRI T1-weighted images. When compared to normal subjects, the two patients have marked loss of subcutaneous fat, except for retro-orbital and bone marrow fat.

Similar articles

Cited by

References

    1. Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest (2019) 42:61–73. doi: 10.1007/S40618-018-0887-Z - DOI - PMC - PubMed
    1. Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab (2016) 101:4500–11. doi: 10.1210/JC.2016-2466 - DOI - PMC - PubMed
    1. Ren Y, Zhao H, Yin C, Lan X, Wu L, Du X, et al. Adipokines, hepatokines and myokines: focus on their role and molecular mechanisms in adipose tissue inflammation. Front Endocrinol (Lausanne) (2022) 13:873699. doi: 10.3389/FENDO.2022.873699 - DOI - PMC - PubMed
    1. Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab (2019) 1:754–64. doi: 10.1038/S42255-019-0095-Y - DOI - PubMed
    1. Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Mera A, Gonzalez-Gay MA, et al. Obesity, fat mass and immune system: role for leptin. Front Physiol (2018) 9:640. doi: 10.3389/FPHYS.2018.00640 - DOI - PMC - PubMed